By pioneering the oral obesity market with Orforglipron, securing early Medicare access, and quietly building out a blockbuster cardiovascular and Alzheimers pipeline, Eli Lilly is actively derisking its future
10.1016/S0301-0082(00)00067-8 41 DanzeisenR.SchwalenstoeckerB.GillardonF.BuergerE.KrzykallaV.KlinderK.et al
The result is suppression of the entire downstream inflammatory cascade at one of its most central control points, operating at nanomolar concentrations
Here is how the comparison actually breaks down
This makes it part of a rising class of compounds that support longevity-focused research, metabolic mapping, and non-invasive modeling - all while remaining outside the consumer market entirely
(Once, I even tried intermittent fasting, which isnt for the faint of heart.) Id stay strong for a while, but Id eventually fall back into my normal habits of overeating